Kornimate/medical-research-clean huggingface dataset:
low level laser therapy versus benzydamin in prevention and treatment of oral mucositis

Conditions: Stomatitis (Oral Mucositis)

Summary: a prospective study will be conducted at the department of oral medicine, periodontology, diagnosis and oral radiology faculty of dental medicine, assiut branch al-azhar university. patients with head and neck cancer under rt, ct treatment participated in this study were selected from south egypt cancer institute. during clinical examination the medical history of the patient will be recorded. data related to base illness, type and stage of rt treatment, association or not to chemotherapy will be collected during the whole treatment. after clinical examination, the patients will receive a kit containing toothbrush, dentifrice, and subsequent oral hygiene instruction. then the patients will be classified into 3 groups as follow: group i (control group): the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. group ii: the patients will be treated by using 0.15% bezaydamine hydrochloride. all patients were advised to rinse 15 ml of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. group iii: the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. the irradiation mode will be punctual and in contact, perpendicular to the oral mucosa.


Eligibility criteria:
inclusion criteria: -patients with head and neck carcinoma were scheduled to receive a rt treatment (two dimensional techniques), covering a wide area of the head and neck region, the rt protocol of the hospital for head and neck cancer patients consisted of treatment sessions 5 days a week, 2gy per fraction, with a total dose of 70 gy over 7 weeks (35 sessions). a minimum dose of 50 gy was delivered to the oral cavity of all patients in the study, either exclusively or associated with chemotherapy. exclusion criteria: * karnofsky performance status (kps)less than 60% . * hypersensitivity to benzydamine or typical nsaids. * patients were excluded if they had lock jaw, any previous medical condition (s) hampering wound healing (e.g., diabetes mellitus).
adherence degree of kasr-alaini hospital pre-anesthetic tests to the nice-uk guidelines

Conditions: Anesthesia; Surgery; Exanimation

Summary: routine preoperative tests aim to identify asymptomatic diseases that can't be recognized by history and examination. identification and management of these diseases is thought to help minimizing perioperative morbidity and mortality. a large number of routine screening tests increase the cost of perioperative care. also unneeded tests may harm the patient due to overtreatment for borderline / false positive results. therefore, the routine use of such examinations remains controversial. the national institute of health and clinical excellence (nice-uk) guidelines for preoperative examination are the assessment standard developed by nice in collaboration with the national collaboration center for acute care in the uk; in order to reduce unnecessary tests by recommending which tests should be offered to people before minor and major operations. the aim of this study is to assess the degree of adherence of the current preoperative tests at kasr alaini hospital to the nice guidelines, to assess the effectiveness and usefulness of the current practice of various examinations ordered by anesthesiologists during the pre-anesthetic evaluation in patients who are intended for elective surgery in the hospital and to also evaluate the cause of delay \& its effect to predict postoperative complications.


Eligibility criteria:
inclusion criteria: * all adult patients scheduled for elective surgical operations. exclusion criteria: * patients operated upon an emergency basis. * pregnant females. * patients scheduled for cardio-thoracic and neurosurgical procedures.

Keywords: pre-anesthetic tests nice-uk guidlines kasr alaini hospital
screening and understanding of the pre-diabetes: decodiab

Conditions: Pre-diabetes

Summary: the main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in the population of patients with pre-diabetes.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) * subjects with diabetes risk score ≥ 12 or with impaired fasting glucose: blood glucose ≥ 1.10 g/l and \< 1 .26 g/l * and with impaired fasting glucose : blood glucose ≥ 1.10 g/l and \< 1 .26 g/l ; or blood glucose ≥ 1g/l and \< 1,1 g/l with hba1c ≥ 6,5% * signed informed consent * subjects affiliated with an appropriate social security system exclusion criteria: * fasting glycemia ≥ 1.26 g/l * fasting glycemia ≤ 1.10 g/l and hba1c \< 6,5% * fasting glycemia \< 1 g/l * subjects previously treated with oral anti-diabetic: metformin, glitazones, inhibitors of α-glucosidase, sulfonylurea, repaglinide, inhibitors of dpp-iv. * subjects previously treated with insulin, except gestational diabetes * severe coagulation disorders * thrombocytopenia \< 100 000/mm 3 * severe psychiatric disorders * severe renal insufficiency (creatinine clearance \< 30 ml/min) * severe hepatic insufficiency * alcohol abuse (\> 30g/j) * contra-indication in the realization of the local anesthetic * subject unable to follow the study during the 5 years of follow-up * subject exclusion period in a previous study

Keywords: pre-diabetes type 2 diabetes biomarkers diabetes risk score
endoscopic long volume reduction by endobronchial valves in belgium

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this a single center non-randomised non-sham controlled intervention study evaluating the effectiveness and safety of endoscopic lung volume reduction by endobronchial valves

the primary objective of the current study is to explore the effect of targeted lobar endobronchial lung volume reduction in symptomatic patients with severe emphysema and absent collateral ventilation, on lung function, exercise capacity and physical activity. as a secondary objective, changes in physical activity as result of a 3 month activity coaching program delivered between 3 to 6 months post intervention will be investigated. exploratory objectives are to extend insight in the clinical characteristics of responders and non-responders and to address relationships between lung function response, physical functioning and its impact on inflammation, skeletal and cardiac function. furthermore, comparison of the effects on lung function, exercise capacity, quality of life and physical activity between endoscopic lung volume reduction and surgical lung volume reduction will be made. the study will also explore if treatment response can be optimised by an intermediate evaluation with ct scan one month after intervention. endoscopic evaluation and repositioning of the endobronchial valves will be imposed in case no lober atelectasis is visualised. .

Eligibility criteria:
inclusion criteria: * age 40 - 75 years * confluent or destructive heterogeneous emphysema on ct * smoking cessation for at least 6m (proven by urinary cotinine levels) * fev1 \ 150 %predicted, tlc \> 90 %predicted * rv/tlc ratio ≥ 0.55 * 6mwd \< 450 meter * mmrc ≥ 2 * visual estimation of 70% complete fissure between target lobe and adjacent lobe on ct of referring physician * laba-lama bronchodilator therapy as a minimum therapy * able to sign informed consent exclusion criteria: * homogenous emphysema * paco2 \> 60 mmhg with ambient air * pao2 \< 45 mmhg with ambient air * previous lvrs, lung transplantation, lobectomy * tlco or fev1 \< 20% predicted * significant pulmonary hypertension (papsyst \> 50 mm hg) * heart failure with reduced ef (\< 40%) * 6mwd \< 100 meter * bode index ≥ 7 and eligible for transplantation * active cancer * life expectancy \< 3 months * significant lung disease other than copd/emphysema * unable to comply with study procedures

Keywords: valves chronic obstructive pulmonary disease endoscopic long volume reduction
evaluation of oral needs of children with disorder attention deficit/hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: there is little accurate data in the literature at present on oral problems of hyperactive children, especially regarding care needs that would justify an assumption oral specific. the purpose of this study is therefore to have accurate data regarding the risk of caries, other oral diseases like periodontal disease, trauma, and assess the needs dental care and problems in cooperation for dental care in a population of children and adolescents with hyperactivity disorder with attention deficit. finally, it has recently been described as the sleep disordered breathing was not uncommon in disorder attention deficit/hyperactivity disorder, whether snoring and/or apnea. but it is now accepted that some features of facial morphology favoring pharyngeal congestion occur in individuals with obstructive sleep apnea (hyperdivergent typology with increased anterior facial height and decreased posterior facial height, becoming the facial retrognathia, pharyngeal congestion, elongation and thickening of the soft palate, low position of the hyoid bone). a cephalometric analysis of craniofacial architecture and relationships with the soft tissue surrounding skeletal structures will detect if any of these specific characteristics that could promote sleep disordered breathing are found in disorder attention deficit/hyperactivity disorder prevalence with a particular.


Eligibility criteria:
inclusion criteria: * consent signed by parents before the examination * with of a social security scheme * age greater than or equal to 5 years and less than 15 years, children with a diagnosis of attention deficit / hyperactivity confirmed or made by a physician specialists co-investigators of the study, diagnosis defined according to precise criteria for a disorder attention deficit/hyperactivity disorder as specified in dsm-iv with a normal iq, ie higher than 80, and without other neurological or psychiatric * child consultant in a hospital or doctors' offices exclusion criteria: * refusal of consent of the parents * no affiliation to a social security scheme * age below 5 years or more than 15 years * diagnosis of a disorder attention deficit/hyperactivity disorder not confirmed by a physician , iq \<80, pathology associated neurological or psychiatric

Keywords: oral health needs children attention deficit disorder with or without hyperactivity
adjuvant therapy for intermediate risk her2 positive, lymph node negative early breast cancer with chemotherapy combined target therapy

Conditions: HER2-positive Breast Cancer

Summary: human epidermal growth factor receptor 2 (her2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis. the emergence of her2 targeted drugs has greatly improved the prognosis and survival of such patients. at present, for her2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and pertuzumab are concentrated in the group of patients with positive lymph nodes. can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. it is planned to explore the efficacy and safety of t1-t2, her2 positive early breast cancer patients with negative lymph nodes to achieve chemotherapy reduction based on risk stratification.


Eligibility criteria:
inclusion criteria: * 1) treatment in peking university people's hospital for radical resection of breast cancer and had hospitalization records; * 2) postoperative pathology confirmed invasive breast cancer, and the pathological stage was t1c, n0, her2 positive, with other high-risk factors (g3, or hormone receptor negative); or the pathological stage is t2, n0, and there are no high-risk factors (g3, or hormone receptor negative); * 3)signed an agreement to participate in the pkuph breast disease cohort study at peking university people's hospital. exclusion criteria: * 1) lack of clinical pathological data (such as imaging data, pathological data); * 2) preoperative neoadjuvant therapy; * 3) patients with metastatic breast cancer or bilateral breast cancer; * 4) failed to undergo curative surgery.

Keywords: taxane target therapy
a prospective, single arm, open label, proof of concept clinical study of sulfasalazine in the treatment of active systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: the goal of this clinical trial is to learn if sulfasalazine is safe and feasible in the treatment of active lupus erythematosus (sle). the main questions it aims to answer are: does drug sulfasalazine with stable background treatment help lower the disease activity (sledai) at week 16? how many patients can reach sri-4 at week 16? can this regimen help lower the prednisone dosage the patients need at week 16? what about the change of the type i interferon related genes expression at week 16? participants will: take sulfasalazine 750mg/dose, twice a day for 16 weeks. the dosage will be increased to 1000mg/dose within one month, twice a day if the patient could tolerate. visit the clinic once every 4 weeks for checkups and tests.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of sle according to the 2012 slicc sle classification criteria. * 18 to 65 years old, regardless of gender. * active sle, i.e. sledai-2k score ≥ 4 points at enrollment. * receiving standard of care: 1. prednisone dosage≤20mg/day, with or without hydroxychloroquine (hcq,≤400mg/day), classic immunosuppressive agents (is),ie, mycophenolate mofetil(≤2.0g/day), azathioprine (≤2mg/kg/day), cyclosporine(≤5.0mg/kg/day), tacrolimus(≤3.0mg/day), methotrexate(≤20mg/week), leflunomide(≤40mg/day), or biological agents such as belimumab(≤ 10mg/kg/month) and telitacicept (≤160mg/week); 2. no more than three types of combined classic is or biological agents, not including hcq. 3. prednisone dosage should not be increased within one month of the screening period, and the immunosuppressants regimen should be stable for at least one month. * agree to sign the informed consent form. * agree to receive contraception through intrauterine devices or oral contraceptives (progesterone or compound progesterone) or condoms. exclusion criteria: * severely active sle: sledai-2k \>12 at screening. * 24-hour urine protein≥ 3g/24 hours. * egfr \< 60ml/min/1.73m2 (epi formula). * baseline prednisone dosage\>40mg/d at screening. * other autoimmune diseases, such as rheumatoid arthritis, sjogren's syndrome, myositis, scleroderma, autoimmune liver disease, etc. * leukopenia or thrombocytopenia (wbc≤3×109/l or plt≤50×109/l) not caused by sle. * liver dysfunction (alt or ast more than twice the normal upper limit). * allergic to sulfonamide drugs. * pregnant or breast-feeding.

Keywords: systemic lupus erythematosus sulfasalazine interferon
duloxetine for postoperative analgesia after modified radical mastectomy

Conditions: Modified Radical Mastectomy; Postoperative Analgesia

Summary: the aim of this study is to evaluate the role of duloxetine in controlling pain after radical mastectomy.

inadequate control of postoperative pain is associated with increased length of hospital stay, increased hospital cost, sleep disturbance, depression, functional impairment and affects the quality of life. modified is one of the commonly performed procedures which is associated with severe postoperative pain. preemptive analgesia is the analgesic treatment initiated before the surgical procedure to prevent central sensitization from the noxious stimuli. drugs such as gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, dexamethasone, and cyclooxygenase-2 inhibitors have been used for preemptive analgesia. there are contrary results about the role of duloxetine in mangement of acute postoperative pain. arecent meta-analysis was done in 2020 that concluded that the currently available evidence does not support the clinical use of duloxetine for the management of acute postoperative pain,so we will discuss that in this study. there are many studies that have shown that perioperative use of duloxetine for a few days has a significant effect on reducing postoperative pain and analgesic requirements. duloxetine is a dual anti-depressant drug that inhibits the neuronal reuptake of serotonin (5-ht) and norepinephrine (ne) modulating the descending inhibitory pain pathways by increasing the availability of serotonin and norepinephrine. duloxetine is an approved drug for the treatment of post-traumatic depression, major depression, and generalized anxiety disorder. it is also approved for the treatment of various chronic painful syndromes, including neuropathic pain associated with diabetes, chronic musculoskeletal pain, and fibromyalgia. the mechanisms of action so far described suggest that duloxetine may be useful as an adjunct in the treatment of acute postoperative pain.

Eligibility criteria:
inclusion criteria: * adult female patients aged (18 - 60) years undergoing modified radical mastectomy. american society of anesthesiologists classification i-ii-iii exclusion criteria: known allergies to duloxetine. * abnormal liver or renal function tests. * narrow angle glaucoma. * being a chronic opioid abuser (more than 3 months) * being on chronic gabapentin or pregabalin (more than 3 months) * being on monoamine oxidase inhibitor, tricyclic antidepressant, or fluvoxamine. * pregnant female * patients with psychiatric disorders or seizure disorders.
clinical decision support in non-typhoidal salmonella bloodstream infections in children

Conditions: Bloodstream Infection; Salmonella Bacteremia; Malaria,Falciparum; Severe Malaria

Summary: in sub-saharan africa, non-typhoidal salmonella (nts) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%). in kisantu hospital in the democratic republic of congo (dr congo), nts account for 75% of bloodstream infection in children and many children are co-infected with plasmodium falciparum (pf) malaria. nts bloodstream infection presents as a non-specific severe febrile illness, which challenges early diagnosis and, as a consequence, prompt and appropriate antibiotic treatment.moreover, at the first level of care, frontline health workers have limited expertise and diagnostic skills and, as a consequence, clinical danger signs that indicate serious bacterial infections are often overlooked. basic handheld diagnostic instruments and point-of-care tests can help to reliably detect danger signs and improve triage, referral and the start of antibiotics, but there is need for field implementation and adoption to low-resource settings. further, it is known that some clinical signs and symptoms are frequent in nts bloodstream infections. the integration of these clinical signs and symptoms in a clinical decision support model can facilitate the diagnosis of nts bloodstream infections and target antibiotic treatment. the investigators aim to develop such a clinical decision support model based on data from children under five years old admitted to kisantu district referral hospital in the democratic republic of the congo. while developing the model, the investigators will focus on the signs and symptoms that can differentiate nts bloodstream infection from severe pf malaria and on the clinical danger signs that can be assessed by handheld diagnostic instruments and point-of-care tests. the deliverable will be a clinical decision support model ready to integrate in an electronic decision support system.


Eligibility criteria:
inclusion criteria: 1. be a child of \> 28 days and \< 5 years old 2. be admitted to kisantu hospital 3. having a blood cultured sampled according to the criteria for suspected bloodstream infection embedded in the blood culture surveillance, i.e. presence of objective fever, hypothermia or history of fever during past 48 hours + at least one of the following criteria: * hypotension, confusion or increased respiratory rate * suspicion of severe localized infection: pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection * suspicion of typhoid fever * suspicion of severe pf malaria 4. having a caregiver willing and able to provide written informed consent exclusion criteria: * none

Keywords: bloodstream infection salmonella non-typhi children under five years clinical decision support democratic republic of the congo fever febrile illness malaria anemia malnutrition bacterial infection
tongji-ezhou study

Conditions: Diabetes; Cardiovascular Diseases; Obesity; Metabolic Syndrome; Nutritional and Metabolic Diseases; Environmental Exposure; Risk Factor, Cardiovascular

Summary: tongji-ezhou study (tjez) is a prospective cohort study launched at 2013 in ezhou city, hubei province, with the goal of recruiting and assessing 10,000 individuals and then following them for at least 2 decades. in addition, blood samples would be collected every 3-5 years among 6000 of them to investigate the nutritional biomarkers and potential determinants of chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease.


Eligibility criteria:
inclusion criteria: * (i) permanent residence in ezhou district (minimum of 9 months); (ii) written informed consent; (iii) age ≥ 20 years old at the time of enrolling in the study. exclusion criteria: * (i) with chemotherapy or radiotherapy for cancer and other severe diseases.